Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
30
FLGT Quote, Financials, Valuation and Earnings
Last price:
$18.34
Seasonality move
:
17.71%
Day range:
$18.32 - $19.15
52-week range:
$16.56 - $30.68
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.98x
P/B ratio:
0.49x
Volume:
686.9K
Avg. volume:
299.5K
1-year change:
-35.94%
Market cap:
$561M
Revenue:
$289.2M
EPS (TTM):
-$5.52
Analysts' Opinion
-
Consensus RatingFulgent Genetics has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Fulgent Genetics has an estimated upside of 43.58% from its current price of $18.34.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $18.34.
Fair Value
-
According to the consensus of 0 analysts, Fulgent Genetics has 43.58% upside to fair value with a price target of -- per share.
FLGT vs. S&P 500
-
Over the past 5 trading days, Fulgent Genetics has underperformed the S&P 500 by -4.43% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Fulgent Genetics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Fulgent Genetics revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Fulgent Genetics reported revenues of $71.7M.
Earnings Growth
-
Fulgent Genetics earnings have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Fulgent Genetics reported earnings per share of -$0.48.
Enterprise value:
347.3M
EV / Invested capital:
0.31x
Price / LTM sales:
1.98x
EV / EBIT:
--
EV / Revenue:
1.25x
PEG ratio (5yr expected):
-0.02x
EV / Free cash flow:
-12.11x
Price / Operating cash flow:
59.77x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$100.6M
Return On Assets:
-13.11%
Net Income Margin (TTM):
-59.39%
Return On Equity:
-14.26%
Return On Invested Capital:
-14.22%
Operating Margin:
-23.81%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $802.9M | $286.4M | $277.8M | $84.7M | $71.7M | |
| Gross Profit | $543.5M | $92.2M | $100.6M | $39.8M | $26.8M | |
| Operating Income | $368.9M | -$81M | -$88.7M | $214K | -$17.1M | |
| EBITDA | $395.3M | -$44.9M | -$81M | $13.3M | -$12.6M | |
| Diluted EPS | $8.70 | -$2.14 | -$5.52 | -$0.44 | -$0.48 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $195.6M | $622.8M | $696.6M | $549.9M | $326.5M | |
| Total Assets | $247.3M | $1.2B | $1.4B | $1.4B | $1.2B | |
| Current Liabilities | $57.7M | $147.2M | $102.5M | $61.4M | $74M | |
| Total Liabilities | $60.4M | $160.2M | $124.4M | $96.6M | $98.9M | |
| Total Equity | $187M | $1B | $1.3B | $1.3B | $1.1B | |
| Total Debt | -- | $21.1M | $20.5M | $2.9M | $2.9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $297.4M | $45.3M | $11M | $10.2M | -$15.5M | |
| Cash From Investing | -$309M | -$78M | -$6.6M | $20.1M | $9M | |
| Cash From Financing | -$34.4M | -$51.4M | -$30.5M | -$4.5M | -$567K | |
| Free Cash Flow | $277.3M | $11.5M | -$28.7M | $5.3M | -$35M | |
FLGT
Sector
Market Cap
$561M
$44.6M
Price % of 52-Week High
59.78%
45.71%
Dividend Yield
0%
0%
Shareholder Yield
4.1%
-0.68%
1-Year Price Total Return
-35.94%
-29.09%
Beta (5-Year)
1.420
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$19.36
200-day SMA
Sell
Level
$21.11
Bollinger Bands (100)
Sell
Level
19 - 22.94
Chaikin Money Flow
Sell
Level
-12M
20-day SMA
Sell
Level
$19.28
Relative Strength Index (RSI14)
Sell
Level
41.26
ADX Line
Sell
Level
7.14
Williams %R
Buy
Level
-99.3421
50-day SMA
Sell
Level
$19.49
MACD (12, 26)
Sell
Level
-0.09
25-day Aroon Oscillator
Buy
Level
52
On Balance Volume
Neutral
Level
30.9M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (6.2136)
Buy
CA Score
(Annual)
Level (1.2747)
Buy
Beneish M-Score
(Annual)
Level (-2.6325)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-0.4319)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.
Stock Forecast FAQ
In the current month, FLGT has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The FLGT average analyst price target in the past 3 months is --.
-
Where Will Fulgent Genetics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Fulgent Genetics share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Fulgent Genetics?
Analysts are divided on their view about Fulgent Genetics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Fulgent Genetics is a Sell and believe this share price will drop from its current level to --.
-
What Is Fulgent Genetics's Price Target?
The price target for Fulgent Genetics over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is FLGT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Fulgent Genetics is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of FLGT?
You can purchase shares of Fulgent Genetics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Fulgent Genetics shares.
-
What Is The Fulgent Genetics Share Price Today?
Fulgent Genetics was last trading at $18.34 per share. This represents the most recent stock quote for Fulgent Genetics. Yesterday, Fulgent Genetics closed at $18.34 per share.
-
How To Buy Fulgent Genetics Stock Online?
In order to purchase Fulgent Genetics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
